What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially report Vertex Pharmaceuticals' financial results for the third quarter and the first nine months of 2016. It does this by incorporating a press release (Exhibit 99.1) that contains the detailed financial information.

Where can I find the specific financial results (revenue, earnings, etc.)?

The specific financial results for the three and nine months ended September 30, 2016, are detailed in the press release dated October 25, 2016, which is included as Exhibit 99.1 to this 8-K filing. You will need to review that document for the precise figures.

Does this filing contain any new business updates or strategic changes?

This 8-K filing itself does not detail new business updates or strategic changes. Its content is limited to the announcement of financial results through the incorporated press release. Any operational or strategic information would be found within Exhibit 99.1.

What is the significance of the information not being 'filed' under Section 18?

The statement that the information in the press release is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 means that Vertex Pharmaceuticals is limiting its liability under that specific section for the contents of the press release. It's a common disclaimer for information furnished in press releases incorporated into 8-Ks.

VRTX 8-K: Earnings & Results

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on October 25, 2016, to report its consolidated financial results for the three and nine months ended September 30, 2016. This filing primarily serves to incorporate by reference a press release detailing these financial outcomes. Investors should refer to the attached press release (Exhibit 99.1) for the specific financial performance data and operational updates.

Key Highlights

1Vertex Pharmaceuticals reported its financial results for the third quarter and the first nine months of 2016.
2The 8-K filing's main purpose is to attach and reference a press release containing the detailed financial information.
3Investors need to consult Exhibit 99.1 (the press release) for specific figures related to revenue, earnings, and other financial metrics.
4The filing indicates that the information presented in the press release is not deemed 'filed' for Section 18 of the Exchange Act, limiting its liability implications.
5No new material business developments beyond the financial results are detailed in the 8-K itself, with all substantive content residing in the incorporated press release.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Oct 25, 2016)

Summary

Key Highlights

Frequently Asked Questions